hero image

Telerx Completes Acquisition of C3i to Enhance Pharmaceutical Solutions Services and Global Capabilities

HORSHAM, Pa. (June 30, 2014) – Telerx, a leader in U.S. customer care services, today announced that it has completed its acquisition of C3i, a leading provider of technology support services for the life sciences industry. This acquisition will provide Telerx with the global infrastructure to expand its business services outside the United States while maintaining its current domestic operations. The acquisition was completed on June 30, 2014.

C3i serves more than half of the world’s largest pharmaceutical companies, delivering 24/7 global, multi-lingual service desk support, end-user training and hardware provisioning services. As a result of the acquisition, Telerx will now deliver services through eight operations centers in the United States, one in Europe and two in Asia.

“As a provider of services and solutions to the pharmaceutical and healthcare industries for more than 30 years, Telerx understands the ever increasing reliance on outside expertise to support a variety of needs, especially in the areas of pharmacovigilance, adherence, patient engagement and support, and access and reimbursement,” said Linda Schellenger, president of Telerx. “We are proud to welcome C3i to our company, continue our growth, and most importantly provide our clients with state-of-the-art service in the U.S. and abroad.”

Telerx Healthcare ConneXions™ supports a wide variety of healthcare clients, including those in the pharmaceutical, medical device and biotech industries. The company’s HIPAA compliant, state-of-the-art contact centers are staffed with nurses, pharmacists, nutritionists and other healthcare specialists, depending on program needs. The company also provides technology to assist clients with processes and existing infrastructure, and to help connect them with patients and providers, enabling quality and outcome improvements.

About Telerx
Telerx, a subsidiary of Merck & Co, Inc., offers complete management of complex and sensitive interactions in the healthcare marketplace, including access and reimbursement, pharmacovigilance, product recalls and critical events, quality and compliance, and patient assistance, among others. The company adheres to strict regulatory requirements and standard operating procedures related to the pharmaceutical industry. More than 90 percent of the company’s clients are FDA-regulated. Telerx has corporate headquarters in Horsham, Pa., with additional contact centers in Allentown and Wilkes-Barre, Pa.; El Paso, Texas; Kings Mountain, N.C.; and Little Falls, N.J. For more information, visit Telerx.com or connect via Facebook,Twitter and LinkedIn.

About C3i
Headquartered in Morristown, N.J., C3i Inc. has global operations in North America, Europe, India and China. Its 1,800 employees provide technology training, multi-lingual service desk, hardware provisioning, and break/fix, asset management and user/application administration services for pharmaceutical sales and clinical professionals worldwide. To learn more, visit www.c3i-inc.com.

About Merck
Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

For Media Inquiries:
Ela Voluck
For Telerx